UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 105

Sortiert nach

Validation of the IMS CORE Diabetes Model

Value in health, 2014-09, Vol.17 (6), p.714-724

2014

Volltextzugriff (PDF)

Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China

Cost effectiveness and resource allocation, 2021-08, Vol.19 (1), p.1-46, Article 46

2021

Volltextzugriff (PDF)

Potential clinical and economic impact of optimised maintenance therapy on discharged patients with COPD after hospitalisation for an exacerbation in China

BMJ open, 2021-04, Vol.11 (4), p.e043664

2021

Volltextzugriff (PDF)

Smart connected insulin dose monitoring technologies versus standard of care: a Canadian cost-effectiveness analysis

Journal of comparative effectiveness research, 2024-03, Vol.13 (3), p.e230124-e230124

2024

Volltextzugriff (PDF)

Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study

PloS one, 2017-06, Vol.12 (6), p.e0179049

2017

Volltextzugriff (PDF)

Assessing the health and economic burden of obesity-related complications in East-Asian populations: implementation of risk equations in the Core Obesity Model for Japan and model validation

BMJ Public Health, 2024-07, Vol.2 (1), p.e000302

2024

Volltextzugriff (PDF)

Cost-effectiveness of semaglutide 2.4 mg in chronic weight management in Portugal

Diabetology and metabolic syndrome, 2024-04, Vol.16 (1), p.97-97, Article 97

2024

Volltextzugriff (PDF)

Treatment patterns and unmet needs in adults with classic congenital adrenal hyperplasia: A modified Delphi consensus study

Frontiers in endocrinology (Lausanne), 2022-11, Vol.13, p.1005963-1005963

2022

Volltextzugriff (PDF)

A novel decision model to predict the impact of weight management interventions: The Core Obesity Model

Obesity science & practice, 2021-06, Vol.7 (3), p.269-280

2021

Volltextzugriff (PDF)

Resource use and cost of hepatitis C-related care

European journal of gastroenterology & hepatology, 2012-10, Vol.24 (10), p.1191-1198

2012

Volltextzugriff (PDF)

The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma

BMC cancer, 2010-11, Vol.10 (1), p.642-642, Article 642

2010

Volltextzugriff (PDF)

Cost-Effectiveness of Early Irbesartan Treatment Versus Control (Standard Antihypertensive Medications Excluding ACE Inhibitors, Other Angiotensin-2 Receptor Antagonists, and Dihydropyridine Calcium Channel Blockers) or Late Irbesartan Treatment in Patients With Type 2 Diabetes, Hypertension, and Renal Disease

Diabetes care, 2004-08, Vol.27 (8), p.1897-1903

2004

Volltextzugriff (PDF)

Cost-Effectiveness Analysis of Motixafortide Versus Plerixafor in Stem Cell Mobilization for Autologous Transplantation in Patients with Multiple Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.10794-10795

2022

Volltextzugriff (PDF)

Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Europe

European journal of preventive cardiology, 2019-07, Vol.26 (11), p.1150-1157

2019

Volltextzugriff (PDF)

A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease

PharmacoEconomics, 2006-01, Vol.24 (2), p.155-169

2006

Volltextzugriff (PDF)

External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions

PharmacoEconomics, 2020-10, Vol.38 (10), p.1123-1133

2020

Volltextzugriff (PDF)

A Health Economic Evaluation of Aspirin in the Primary Prevention of Cardiovascular Disease in Japan

Internal Medicine, 2007, Vol.46(4), pp.157-162

2007

Volltextzugriff (PDF)

A Health Economic Model to Assess the Long-Term Effects and Cost-Effectiveness of Orlistat in Obese Type 2 Diabetic Patients

Diabetes care, 2002-02, Vol.25 (2), p.303-308

2002

Volltextzugriff (PDF)

Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom

Journal of medical economics, 2024-05, Vol.27 (1), p.1-15

2024

Volltextzugriff (PDF)

Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective

International Journal of Obesity, 2024-05, Vol.48 (5), p.683-693

2024

Volltextzugriff (PDF)

135-LB: Cost Effectiveness of the FreeStyle Libre System vs. Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Treatment Not Reaching Glycemic Goals in Sweden

Diabetes (New York, N.Y.), 2021-06, Vol.70 (Supplement_1)

2021

Volltextzugriff (PDF)

Cost-Effectiveness of the FreeStyle Libre® System Versus Blood Glucose Self-Monitoring in Individuals with Type 2 Diabetes on Insulin Treatment in Sweden

Diabetes therapy, 2021-12, Vol.12 (12), p.3137-3152

2021

Volltextzugriff (PDF)

Authors’ reply to Comment on “External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions”

PharmacoEconomics, 2021-01, Vol.39 (1), p.137-138

2021

Volltextzugriff (PDF)

Cost-effectiveness of the cell-based quadrivalent versus the standard egg-based quadrivalent influenza vaccine in Germany

Journal of medical economics, 2021-01, Vol.24 (1), p.490-501

2021

Volltextzugriff (PDF)

Cost–effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes

Journal of comparative effectiveness research, 2020-08, Vol.9 (11), p.781-794

2020

Volltextzugriff (PDF)

1 – 25 von 105

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(94)
Mit Volltextzugriff
(95)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Validation of the IMS CORE Diabetes Model

Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China

Potential clinical and economic impact of optimised maintenance therapy on discharged patients with COPD after hospitalisation for an exacerbation in China

Smart connected insulin dose monitoring technologies versus standard of care: a Canadian cost-effectiveness analysis

Treatment continuation of four long-acting antipsychotic medications in the Netherlands and Belgium: A retrospective database study

Assessing the health and economic burden of obesity-related complications in East-Asian populations: implementation of risk equations in the Core Obesity Model for Japan and model validation

Cost-effectiveness of semaglutide 2.4 mg in chronic weight management in Portugal

Treatment patterns and unmet needs in adults with classic congenital adrenal hyperplasia: A modified Delphi consensus study

A novel decision model to predict the impact of weight management interventions: The Core Obesity Model

Resource use and cost of hepatitis C-related care

The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma

Cost-Effectiveness Analysis of Motixafortide Versus Plerixafor in Stem Cell Mobilization for Autologous Transplantation in Patients with Multiple Myeloma

Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Europe

A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease

External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions

A Health Economic Evaluation of Aspirin in the Primary Prevention of Cardiovascular Disease in Japan

A Health Economic Model to Assess the Long-Term Effects and Cost-Effectiveness of Orlistat in Obese Type 2 Diabetic Patients

Cost-effectiveness of empagliflozin as add-on to standard of care for chronic kidney disease management in the United Kingdom

Cost-effectiveness of weight-management pharmacotherapies in Canada: a societal perspective

135-LB: Cost Effectiveness of the FreeStyle Libre System vs. Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Treatment Not Reaching Glycemic Goals in Sweden

Cost-Effectiveness of the FreeStyle Libre® System Versus Blood Glucose Self-Monitoring in Individuals with Type 2 Diabetes on Insulin Treatment in Sweden

Authors’ reply to Comment on “External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions”

Cost-effectiveness of the cell-based quadrivalent versus the standard egg-based quadrivalent influenza vaccine in Germany

Cost–effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes

Suchergebnisse filtern